Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Anuh Pharma Limited is an Indian pharmaceutical manufacturer focused on generic drug formulations and active pharmaceutical ingredients (APIs). The company operates in a highly competitive generics market with modest margins (24.5% gross, 7.2% net) and zero debt, positioning it as a stable but slow-growth player. Recent performance shows revenue stagnation (+2.2% YoY) and significant earnings compression (-21.2% net income decline), suggesting pricing pressure or operational challenges in its core markets.
Anuh Pharma generates revenue by manufacturing and selling off-patent generic drugs and APIs at competitive prices. Profitability depends on procurement of raw materials (largely imported from China), manufacturing efficiency, regulatory compliance for export markets, and ability to maintain pricing in commoditized therapeutic segments. The 24.5% gross margin suggests limited pricing power typical of mid-tier Indian generics players. Zero debt provides financial flexibility but the 7.2% net margin indicates thin profitability after SG&A and regulatory costs. The company likely competes on cost rather than differentiated products.
API and raw material input costs, particularly from Chinese suppliers (currency fluctuations in USD/INR and USD/CNY impact procurement)
Domestic pharmaceutical pricing regulations and National List of Essential Medicines (NLEM) price controls in India
US FDA or European regulatory approvals for new generic formulations enabling export market access
Competitive intensity in key therapeutic segments (antibiotics, cardiovascular, anti-diabetics) affecting realization prices
Indian rupee depreciation against USD (benefits exports but increases raw material costs)
Intensifying price erosion in generic pharmaceuticals globally as biosimilars and complex generics shift competitive dynamics, compressing margins for simple oral solid formulations
Regulatory risk from stricter US FDA and European inspections of Indian manufacturing facilities, with potential warning letters or import alerts disrupting export revenues
Dependence on Chinese API supply chains creates vulnerability to geopolitical tensions, supply disruptions, or anti-dumping duties affecting input costs
Indian government price controls through NLEM expansions and drug price control orders limiting pricing flexibility on high-volume essential medicines
Intense competition from larger Indian generics players (Sun Pharma, Dr. Reddy's, Cipla) with superior scale, R&D capabilities, and established US/EU distribution networks
Commoditization of key therapeutic segments with limited product differentiation, forcing competition primarily on price rather than quality or service
Vertical integration by larger competitors into API manufacturing reducing their costs and squeezing mid-tier players like Anuh Pharma
Low FCF generation ($0.2B, 2.2% yield) relative to market cap limits capacity for growth investments or shareholder returns without dilution
Declining profitability (-21.2% net income YoY) while maintaining capex at $0.2B suggests margin pressure may force difficult capital allocation choices
Working capital intensity typical of pharma distribution (2.11 current ratio) ties up cash, and any deterioration in receivables collection could strain liquidity despite zero debt
low - Pharmaceutical demand is relatively inelastic as healthcare needs persist regardless of economic conditions. However, discretionary healthcare spending and generic substitution rates can be influenced by consumer purchasing power in India. Government healthcare budgets and insurance penetration affect volumes, but essential medicines maintain stable demand through cycles.
Low direct sensitivity given zero debt (Debt/Equity: 0.00), eliminating financing cost concerns. However, rising rates in India affect valuation multiples as investors rotate from growth/defensive stocks to higher-yielding alternatives. Higher rates also impact working capital financing costs for distributors and customers, potentially affecting payment cycles. US Federal Reserve policy influences USD/INR exchange rates, impacting export competitiveness and raw material import costs.
Minimal direct credit exposure given zero debt. However, the company faces indirect credit risk through receivables from distributors and institutional buyers in India's healthcare system, where payment delays are common. Tightening credit conditions could strain distributor financing and slow inventory turnover.
value - The stock trades at 1.0x Price/Sales and 2.4x Price/Book with zero debt, attracting value investors seeking defensive healthcare exposure at reasonable multiples. However, negative earnings growth (-21.2%) and weak momentum (-4.7% 1-year return) deter growth investors. The 2.2% FCF yield is insufficient for income-focused investors. Current holder base likely consists of domestic Indian value funds and contrarian investors betting on margin recovery.
moderate - As a mid-cap Indian pharmaceutical stock, Anuh Pharma experiences moderate volatility driven by rupee fluctuations, regulatory news flow, and quarterly earnings surprises. The healthcare sector provides some defensive characteristics, but exposure to export markets and commodity-like API pricing creates earnings volatility. Recent 6-month decline of -11.1% suggests elevated volatility during periods of margin compression.
